Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATAINASDAQ:ATYRNASDAQ:FULCNASDAQ:IMAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATAIAtai Life Sciences$1.43+1.4%$1.41$1.03▼$2.57$285.71M1.221.52 million shs1.18 million shsATYRAtyr PHARMA$3.03-8.5%$3.27$1.42▼$4.66$269.68M0.79915,739 shs2.01 million shsFULCFulcrum Therapeutics$5.63-2.8%$3.48$2.32▼$10.13$303.90M2.29963,181 shs620,005 shsIMABI-Mab$0.88-4.1%$0.83$0.60▼$2.00$71.91M1.13308,908 shs129,014 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATAIAtai Life Sciences-2.08%+2.17%+9.30%-44.71%-27.32%ATYRAtyr PHARMA+2.16%+2.48%+11.45%-8.06%+330,999,900.00%FULCFulcrum Therapeutics+1.94%+8.22%+115.24%+62.64%-21.22%IMABI-Mab-2.66%+3.23%+38.12%-4.11%-49.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATAIAtai Life Sciences2.8709 of 5 stars3.51.00.00.02.73.31.3ATYRAtyr PHARMA2.7252 of 5 stars3.61.00.00.03.33.30.6FULCFulcrum Therapeutics1.1008 of 5 stars1.92.00.00.03.12.50.0IMABI-Mab3.3929 of 5 stars3.75.00.00.03.31.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATAIAtai Life Sciences 3.00Buy$10.50634.27% UpsideATYRAtyr PHARMA 3.14Buy$18.60513.86% UpsideFULCFulcrum Therapeutics 1.86Reduce$6.6718.41% UpsideIMABI-Mab 3.33Buy$5.50523.37% UpsideCurrent Analyst Ratings BreakdownLatest IMAB, FULC, ATYR, and ATAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2025IMABI-MabHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.004/4/2025IMABI-MabNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/19/2025ATAIAtai Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/14/2025ATYRAtyr PHARMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00 ➝ $35.002/27/2025IMABI-MabBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy2/26/2025FULCFulcrum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$4.00 ➝ $4.002/18/2025ATYRAtyr PHARMALeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy2/18/2025ATYRAtyr PHARMALeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$16.00(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATAIAtai Life Sciences$308K927.62N/AN/A$1.47 per share0.97ATYRAtyr PHARMA$235K1,147.58N/AN/A$1.54 per share1.97FULCFulcrum Therapeutics$80M3.80N/AN/A$3.80 per share1.48IMABI-Mab$3.27M21.97N/AN/A$2.93 per share0.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATAIAtai Life Sciences-$40.22M-$0.93N/AN/AN/AN/A-65.75%-52.71%5/14/2025 (Estimated)ATYRAtyr PHARMA-$50.39M-$0.81N/AN/AN/AN/A-79.44%-59.16%N/AFULCFulcrum Therapeutics-$97.33M-$0.07N/AN/AN/AN/A-7.31%-6.74%7/29/2025 (Estimated)IMABI-Mab-$206.44MN/A0.00N/AN/AN/AN/AN/AN/ALatest IMAB, FULC, ATYR, and ATAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ATAIAtai Life Sciences-$0.19-$0.15+$0.04-$0.15N/A$1.56 million5/7/2025Q1 2025ATYRAtyr PHARMA-$0.19-$0.17+$0.02-$0.17N/AN/A5/1/2025Q1 2025FULCFulcrum Therapeutics-$0.29-$0.28+$0.01-$0.28N/AN/A3/17/2025Q4 2024ATAIAtai Life Sciences-$0.14-$0.24-$0.10-$0.24$0.30 million($0.01) million3/13/2025Q4 2024ATYRAtyr PHARMA-$0.23-$0.18+$0.05-$0.18$0.02 millionN/A2/25/2025Q4 2024FULCFulcrum Therapeutics-$0.28-$0.31-$0.03-$0.31N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATAIAtai Life SciencesN/AN/AN/AN/AN/AATYRAtyr PHARMAN/AN/AN/AN/AN/AFULCFulcrum TherapeuticsN/AN/AN/AN/AN/AIMABI-MabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATAIAtai Life Sciences0.145.815.81ATYRAtyr PHARMA0.025.415.41FULCFulcrum TherapeuticsN/A18.4418.44IMABI-MabN/A15.9915.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATAIAtai Life Sciences28.41%ATYRAtyr PHARMA61.72%FULCFulcrum Therapeutics89.83%IMABI-Mab38.38%Insider OwnershipCompanyInsider OwnershipATAIAtai Life Sciences31.20%ATYRAtyr PHARMA3.70%FULCFulcrum Therapeutics7.00%IMABI-Mab22.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATAIAtai Life Sciences80199.80 million115.45 millionOptionableATYRAtyr PHARMA5389.00 million80.84 millionOptionableFULCFulcrum Therapeutics10053.98 million51.73 millionOptionableIMABI-Mab38081.50 million63.49 millionOptionableIMAB, FULC, ATYR, and ATAI HeadlinesRecent News About These CompaniesI-Mab (NASDAQ:IMAB) Sees Large Growth in Short InterestMay 4, 2025 | americanbankingnews.comI-Mab (NASDAQ:IMAB) Shares Sold by Hhlr Advisors LTD.May 1, 2025 | marketbeat.comI-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ESMO GI 2025April 30, 2025 | gurufocus.comI-Mab (NASDAQ:IMAB) Short Interest Down 64.9% in MarchApril 17, 2025 | marketbeat.comAfter Plunging -20.33% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB)April 14, 2025 | zacks.comAfter Plunging -19.7% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB)April 11, 2025 | zacks.comI-Mab’s Transformative Year: Financial and Strategic HighlightsApril 5, 2025 | tipranks.comI-Mab price target lowered to $7 from $8 at H.C. WainwrightApril 4, 2025 | markets.businessinsider.comI-Mab Positions for Growth with U.S. Focus and Innovative Cancer TreatmentsApril 4, 2025 | tipranks.comPromising Pipeline and Strong Financial Position Drive Buy Rating for I-MabApril 4, 2025 | tipranks.comI-Mab Reports Full Year 2024 Financial Results and Provides Business UpdateApril 3, 2025 | gurufocus.comI-Mab stock touches 52-week low at $0.72 amid market challengesApril 3, 2025 | investing.comI-Mab to Present at 24th Annual Needham Virtual Healthcare ConferenceMarch 26, 2025 | markets.businessinsider.comI-Mab faces Nasdaq delisting over bid price ruleMarch 23, 2025 | investing.comI-Mab receives Nasdaq deficiency noticeMarch 22, 2025 | markets.businessinsider.comI-Mab Receives Nasdaq Deficiency Notice for Minimum Bid PriceMarch 21, 2025 | tipranks.comI-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementMarch 21, 2025 | globenewswire.comI-Mab Biopharma: I-Mab Announces Accelerated Givastomig Phase 1b Study ProgressMarch 7, 2025 | finanznachrichten.deI-Mab Advances Phase Ib Trial of Givastomig in CLDN18.2-Expressing Gastric CancersMarch 7, 2025 | precisionmedicineonline.comI-Mab Completes Enrollment Ahead of Schedule in First Dose Expansion Cohort of Givastomig Study, Doses First Patient in Second CohortMarch 7, 2025 | quiverquant.comI-Mab Announces Accelerated Givastomig Phase 1b Study ProgressMarch 7, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMAB, FULC, ATYR, and ATAI Company DescriptionsAtai Life Sciences NASDAQ:ATAI$1.43 +0.02 (+1.42%) As of 04:00 PM EasternAtai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.Atyr PHARMA NASDAQ:ATYR$3.03 -0.28 (-8.46%) As of 04:00 PM EasternaTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.Fulcrum Therapeutics NASDAQ:FULC$5.63 -0.16 (-2.76%) As of 04:00 PM EasternFulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.I-Mab NASDAQ:IMAB$0.88 -0.04 (-4.09%) As of 04:00 PM EasternI-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
